New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:14 EDTDEPO, MNKFDA PDUFA Date for Depomed/Mallinckrodt MNK-795 is January 29, 2014
News For DEPO;MNK From The Last 14 Days
Check below for free stories on DEPO;MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMNKDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTMNKMallinckrodt initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
07:36 EDTMNKMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
15:42 EDTDEPODepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
16:13 EDTMNKMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
16:09 EDTMNKMallinckrodt initiated with an Outperform at Oppenheimer
Target $100.
08:03 EDTDEPODepomed appoints Srinivas Rao as Chief Medical Officer
Subscribe for More Information
July 15, 2014
16:37 EDTDEPODepomed files automatic mixed securities shelf
Subscribe for More Information
July 14, 2014
15:09 EDTMNKQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
07:04 EDTMNKMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
July 11, 2014
06:39 EDTMNKQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use